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Background: Age-related declines in testosterone and growth hormone (GH) are associated with 
increased adiposity and decreases in lean mass and bone mineral density (BMD). A long-term 
retrospective study examined the effects of testosterone and/or GH supplementation on body 
composition and quality of life (QoL).
Methods: A database survey assessed the records of 91 men and 97 women (ages 25–82) in 
treatment groups based on their hormonal status: dehydroepiandrosterone but no hormonal supple-
mentation (control); testosterone only (Tes); GH only (GH); and testosterone plus GH (Tes+GH). 
Pre- and post-treatment assessments recorded changes in fat and lean mass, BMD, and QoL.
Results: After an average of 3 years of treatment, weight decreased in women in the control 
and Tes+GH groups but remained stable in men in all groups. Tes and Tes+GH produced 
statistically signiﬁ  cant increases in lean mass, reductions in fat mass, and improvements in 
BMD in both sexes; GH produced similar changes in women. QoL and mood improved in all 
groups. Treatments were generally safe and well tolerated.
Conclusions: In this retrospective survey, treatment with testosterone and/or GH was associated 
with favorable effects in men and women across a wide age range.
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Background
Since the second century, when Galen observed that castration led to declines in 
sexual function and general health and recommended eating animals’ testicles as 
a way to improve vitality, medicine has progressed to a point where isolated and 
puriﬁ  ed testosterone can be used clinically. Today, however, the goal is not only 
to enhance libido and sexual function, especially in men, but also to optimize body 
composition – to offset age-related hormonal changes that may contribute to reduced 
bone mass (osteopenia), reduced muscle mass (sarcopenia), and increased adiposity. 
Increased visceral adiposity has been associated with increased risk of coronary artery 
disease, type 2 diabetes, and other types of morbidity (Nicklas et al 2004; Lebovitz 
and Banerji 2005; Jensen 2006).
Testosterone levels are positively correlated with measures of body composi-
tion such as bone mineral density (BMD) and lean muscle mass. Improved BMD 
is associated with a decreased risk for osteoporosis and fracture. The correlation 
between testosterone levels and lean muscle mass is seen across a wide range of age 
and health status (Bross et al 1998). Optimal lean mass is associated with increased 
strength and coordination and reduced injury from falls. Reduced body fat is associ-
ated with decreased actuarial health risk, especially for coronary artery disease and 
type 2 diabetes mellitus.
The most obvious beneﬁ  ciaries of testosterone supplementation would be hypogo-
nadal men. All patients in this reported study in the testosterone-only group had been 
diagnosed as hypogonadal when they began testosterone treatment. Because testosterone Journal of Multidisciplinary Healthcare 2008:1 80
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levels generally decline as men age, with free testosterone 
concentrations declining by about 50% between age 25 and 75, 
elderly men are at higher risk of becoming hypogonadal. 
The over-65 male population is expected to double (to over 
31 million) by 2030, with the incidence of low testosterone 
levels increasing from 30% in the seventh decade of life to 
70% in the eighth decade (Hijazi and Cunningham 2005). 
Accordingly, it is important to understand whether testosterone 
supplementation improves measures of health.
As in men, androgens in women affect body composition, 
mood, libido, and general well-being. Deﬁ  ciency in young 
women may result from ovarian or adrenal dysfunction, 
hypothalamic amenorrhea, ovarian failure, oophorectomy, 
or wasting from acquired immunodeﬁ  ciency syndrome. 
Deﬁ  ciency in testosterone may occur secondary to use of 
estrogen, oral contraceptives, or corticosteroids. However, 
this condition is difﬁ  cult to recognize (declining libido may be 
the only symptom), and the few data on testosterone therapy 
in premenopausal women reveal mainly the expected adverse 
effects of reversible hirsutism and acne; more data are needed 
to identify women who would be candidates for testosterone 
therapy and to establish therapeutically useful regimens in 
this population (Kalantaridou and Calis 2006).
Like patients who have low androgen levels, individuals 
with growth hormone (GH) deficiency have increased 
adiposity. All patients in this study who received GH had 
clinically documented GH deﬁ  ciency. Results of studies 
designed to determine the effects of GH on body composition 
in deﬁ  cient adults have been mixed. Various trials have 
shown improvement in BMD in men (Bravenboer et al 
2005; Snyder et al 2007), decreased fat mass and increased 
lean mass in both men and women, along with signiﬁ  cant 
improvements in serum lipids but not in BMD (Hoffman et al 
2004), and beneﬁ  cial reductions in waist:hip ratio and serum 
low density lipoprotein cholesterol (Franco et al 2006).
The objective of the retrospective survey of clinical data 
was to assess the effects of testosterone and GH supplementa-
tion on body composition and quality of life (QoL) in men 
and women who had been diagnosed as deﬁ  cient in androgens 
and/or GH across a wide age range.
Methods
This study examined the records of patients treated at the 
Cenegenics® Medical Institute (Las Vegas, NV) during the 
period 1999 to 2006.
The records of 91 men were assessed in the following 
treatment groups: dehydroepiandrosterone (DHEA; an 
adrenal precursor to both estrogens and androgens) but 
no testosterone or GH (control; n = 31; age range 40–82); 
testosterone only (Tes; n = 17; age range 40–79); GH only 
(GH; n = 20; age range 42–70); and testosterone plus GH 
(Tes+GH; n = 23, age range 36–81).
The records of 97 women were assessed in the same 
deﬁ  ned treatment groups: control (n = 27; age range 25–60); 
Tes (n = 26; age range 38–69); GH (n = 12; age range 42–71); 
and Tes+GH (n = 32, age range 29–75).
The average length of treatment was 3 years.
Table 1 outlines the hormonal regimen used in male and 
female patients with their consent after explanation of clinical 
and laboratory goals to be achieved.
Measures of body composition (BMD and body mass 
index) and QoL were compared in patients who received 
hormonal treatment versus patients who received DHEA 
supplementation but no hormonal treatment. Other thera-
pies, given adjunctively as needed to optimize clinical and 
laboratory parameters, included DHEA, thyroid hormone, 
melatonin (for antioxidant and sleep-stabilizing properties), 
human chorionic gonadotropin in men (to facilitate weight 
loss and stimulate endogenous testosterone production), and 
estradiol and progesterone in women.
In addition to the hormonal regimens, all patients were 
placed on a low-glycemic diet to improve the lipid proﬁ  le 
and increase insulin sensitivity and an exercise program to 
increase lean muscle mass and decrease fat mass.
All patients had comprehensive baseline and annual 
physical examinations as well as laboratory assessments at 
4- to 6-month intervals. Dual X-ray absorptiometry scans 
were obtained annually to assess BMD at the hip and lumbar 
spine; fat mass and lean muscle mass were also assessed 
annually. QoL outcomes were rated using standardized 
scales (the Beck Depression Inventory and the Holmes and 
Dickerson linear analog self-assessment scale) to assess 
mood and functionality.
Data were expressed as the mean ± standard error. 
Between-group differences were assessed using the Mann-
Whitney U test and the Kruskal-Wallis test. For correlations, 
Pearson’s test was used for normally distributed data; otherwise, 
the Spearman rank test was used. All hypothesis tests were two-
tailed, with statistical signiﬁ  cance assessed at p  0.05 with 
95% conﬁ  dence intervals. The statistical software used was 
SPSS 11.5 for Windows (SPSS Inc, Chicago, IL, USA).
Results
Serum testosterone
Among men, there were no significant changes 
in weight (pre- and post-treatment), and there were Journal of Multidisciplinary Healthcare 2008:1 81
Testosterone and growth hormone normalization
no significant changes between the different groups 
(Figure 1). In the control group, mean total testosterone 
increased from 545 ng/dL pretreatment to 687 ng/dL 
post-treatment (p  0.03), and free testosterone rose from 
107 to 119 pg/mL (nonsigniﬁ  cant). In the Tes group, the 
corresponding increases in total and free testosterone 
were 538 to 927 ng/dL (p  0.002), and 94 to 167 pg/mL 
(p  0.002). In the GH group, the increases were 596 
to 707 ng/dL (nonsignificant) and 110 to 156 pg/mL 
(p  0.006). In the Tes+GH group, the increases were 
526 to 814 ng/dL (p  0.002) and 88 to 126 pg/mL 
(p  0.03).
Among women in the Tes, GH, and Tes+GH groups, 
increases in serum testosterone were significant but of 
considerably smaller magnitude.
Body weight
Among men, there were no signiﬁ  cant within-group or 
between-group changes in weight. Mean weight across all 
groups remained stable within the range of 192 to 198 lbs 
(87–90 kg) over the course of the trial.
However, among women, mean weight between treat-
ment groups was more diverse at baseline (138–155 lbs, or 
63–71 kg), and treatment resulted in more notable weight 
decreases in the control and Tes+GH groups (4.8% and 
3.2%, respectively).
Body composition
Lean mass increased signiﬁ  cantly with Tes (3%) and Tes+GH 
(6%) in men, and with Tes (2%), GH (13%), and Tes+GH 
(3%) in women (Figure 2). Among men, the increase with 
Table 1 Hormonal regimens; in addition to the use of testosterone and GH, other hormonal treatments were offered as needed to 
achieve normalization of clinical and laboratory status
Therapy (route) Goal Measurement
Testosteronea, men (intramuscular) Concentration (±12.5%) representing 66th percentile 
for 40-year-old men
Total: 700–900 ng/dL
Free: 130–200 pg/mL
For clinically documented hormone deﬁ  ciency
Testosterone, women (transdermal or sublingual) Upper 33% of normal range for premenopausal 
women
Total: 52–70 ng/dL
For clinically documented hormone deﬁ  ciency
Human growth hormone (subcutaneous) Upper 40% of normal range for ages 39–54 years Rise of 100% in 
insulin-like growth 
factor 1, but not above 
360 ng/mL
For clinically documented hormone deﬁ  ciency
Dehydroepiandrosterone (DHEA) (oral) Upper 30% of normal range for young adults Sulfated DHEA:
470–619 µg/dL in men
280–380 µg/dL in 
women
aHuman chorionic gonadotropin also used as needed to increase testosterone production.
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Figure 1 Change in serum testosterone (men). Total and free testosterone increased in all treatment groups. Most of the increases were statistically signiﬁ  cant.Journal of Multidisciplinary Healthcare 2008:1 82
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Tes+GH was significantly greater than with any other 
regimen.
Total body fat was signiﬁ  cantly reduced with Tes and 
Tes+GH in men, and with Tes, GH, and Tes+GH in women; 
the percentage change was substantially greater in men 
(Figure 3). Trunk fat was signiﬁ  cantly reduced in the control 
(p  0.03) and Tes+GH (p  0.02) groups in men, and in 
the Tes (p  0.01), GH (p  0.04), and Tes+GH (p  0.01) 
groups in women; truncal adiposity increased signiﬁ  cantly 
in the female control group.
BMDat the hip increased signiﬁ  cantly in the Tes (6%) 
and Tes+GH (3%) groups in men, and in the Tes (5%), 
GH (11%), Tes+GH (9%), and control (3%) groups in 
women (Figure 4).
QoL outcomes
Although none of the groups showed any notable abnor-
malities at baseline, scores on standard measures of mood, 
functionality, and quality of life showed improved status 
over the course of treatment (Table 2).
Safety
Physical and laboratory assessments and recording of adverse 
effects indicated that the study treatments were generally well 
tolerated. Among the men, mean levels of prostate speciﬁ  c 
antigen (PSA) showed statistically nonsigniﬁ  cant increases 
from baseline to post-treatment with all regimens (from 1.05 
to 1.40 ng/mLwith Tes, from 1.03 to 1.20 ng/mL with GH, 
and from 1.04 to 1.14 ng/mL with Tes+GH).
Discussion
This study showed that supplementation with testosterone or 
GH or both, in conjunction with beneﬁ  cial lifestyle changes 
in diet and exercise, produced statistically signiﬁ  cant changes 
in measures of body composition. Treatments were generally 
well tolerated.
To place these ﬁ  ndings in perspective, a systematic 
review and meta-analysis of 29 randomized controlled trials 
of testosterone therapy in over 1000 middle-aged and aging 
men (mean age 64.5 years) found that treatment resulted in 
a 6.2% reduction in total body fat and a 2.7% increase in 
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Figure 2 Lean mass in men and women. Testosterone, alone or in combination with growth hormone (GH), signiﬁ  cantly increased lean mass in both men and women.
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Figure 3 Change in total body fat in men and women. Testosterone, alone or in combination with growth hormone (GH), signiﬁ  cantly reduced fat mass in both men and women.Journal of Multidisciplinary Healthcare 2008:1 83
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lean mass, marginal improvement in strength, signiﬁ  cant 
increase (3.7%) in BMD at the lumbar spine but not at the 
femoral neck, and reductions in cholesterol, especially in 
men with lower testosterone concentrations at baseline 
(Isidori et al 2005). Those ﬁ  ndings are generally consistent 
with the changes noted in the present study, which included 
men and women spanning a wider age range. However, 
another systematic review of the literature questioned the 
beneﬁ  t of testosterone supplementation in men with normal 
testosterone levels (Krause et al 2005).
Testosterone supplementation by any route of admin-
istration (intramuscular, oral, or transdermal) increases 
BMD by increasing formation and decreasing resorption 
of bone, with theoretical but as yet unproven reduction in 
fracture risk (Köhn 2006). In a 1999 report, individuals 
with lower pretreatment serum testosterone concentration 
showed greater changes in lumbar spine BMD during the 
ﬁ  rst 3 years of treatment (Snyder et al 1999). This ﬁ  nding 
is supported by another study in which men with borderline 
hypogonadism showed only limited beneﬁ  t from one year 
of testosterone therapy (reduction in body fat mass but no 
signiﬁ  cant increase in BMD or lean muscle mass); however, 
extending the treatment might yield more robust effects 
(Merza et al 2006).
One of the most important reasons for studying the effects 
of testosterone treatment is that testosterone therapy also 
has beneﬁ  t in terms of cardiovascular health. If changes in 
body composition measures provide a surrogate measure 
for decreased cardiovascular morbidity, clinicians would 
have a valuable tool for determining which patients to treat 
and guidance for determining treatment end points. A case-
control study showed the risk of severe atherosclerotic 
coronary artery disease in men varied inversely with total 
testosterone; risk was 5-fold higher among men in lowest 
quartile than among men in highest quartile (Chute et al 
1987). A large-scale survey in 1132 men aged 30 to 79 years 
revealed a signiﬁ  cant inverse relationship between blood 
pressure and levels of testosterone (p  0.001 for both 
systolic and diastolic pressure), but no such correlation was 
seen with other hormones (Khaw et al 1988). The reduction 
in body fat mass associated with testosterone therapy, 
along with possible stabilizing effects on blood glucose, 
has obvious beneﬁ  cial implications in terms of lowered 
risk of diabetes, metabolic syndrome, and cardiovascular 
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Figure 4 Bone mineral density at the hip in men and women. Testosterone, alone or in combination with growth hormone (GH), signiﬁ  cantly improved bone mineral density 
at the hip in both men and women.
Table 2 Quality-of-life outcomes, mood, functionality, and quality of life showed signiﬁ  cant improvements throughout the treatment period
Improvement by treatment regimen (p value)
Control Tes GH Tes+GH
Beck Depression Inventory Men
Women
p  0.05
p  0.01
p  0.04
p  0.0001
p  0.008
NS
p  0.01
p  0.05
Holmes and Dickerson Scalea Men
Women
NS
p  0.002
p  0.03
p  0.005
NS
p  0.05
p  0.08
p  0.02
aLinear analog self-assessment scale for quality of life.
NS, nonsigniﬁ  cant.Journal of Multidisciplinary Healthcare 2008:1 84
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disease (Köhn 2006). It is noteworthy that the present study 
showed not only reductions in total body fat with testosterone 
and GH, but also reductions in truncal fat, which in excess is 
associated with an increased risk of insulin resistance.
Another potential beneﬁ  t of testosterone therapy may be 
decreasing the risk of Alzheimer’s disease. GH is believed to 
have neuroprotective effects, directly or in conjunction with 
insulin-like growth factor I (IGF-1; a polypeptide produced 
mainly in the liver in response to stimulation by GH). In a 
study of lean elderly subjects, low testosterone availability 
secondary to high levels of sex hormone binding globulin was 
associated with a higher incidence of Alzheimer’s disease 
(Paoletti et al 2004). Although the exclusion of heavier 
patients may limit the applicability of these ﬁ  ndings and the 
root problem was not absolute testosterone deﬁ  ciency but 
excessive binding leaving inadequate free testosterone, there 
may be a role for testosterone supplementation in patients 
considered at risk. The QoL measurements used in the 
present study may provide a useful clinical measurement of 
cognitive function. Recent reviews on this topic concluded 
that supplementation may minimize cognitive loss in testos-
terone-deﬁ  cient elderly patients at risk (Beauchet 2006) and 
that supplementation may be more beneﬁ  cial in elderly men 
than in elderly women (Hogervorst et al 2005).
With reference to GH, a meta-analysis of 10 randomized 
trials in 458 patients with GH deﬁ  ciency showed that the 
mean change in BMD at the lumbar spine was signiﬁ  cant 
at 6 and 12 months, and more strongly signiﬁ  cant at 18 and 
24 months; however, the magnitude of these changes was 
small and of uncertain clinical relevance (Davidson 
et al 2004).
The idea of combining hormonal and bisphosphonate 
therapy is an attractive approach to improving BMD. 
A long-term controlled study in 30 adults with GH deﬁ  ciency 
showed that the combination of GH and alendronate was 
highly effective in patients with osteoporosis (Biermasz et al 
2004). In contrast, a study in 149 men showed testosterone 
and alendronate were comparably effective, but the combi-
nation offered no additional beneﬁ  t over monotherapy with 
either agent (Welch et al 2007).
The role of DHEA supplementation to improve BMD is 
unclear. In a randomized controlled one-year trial in 140 men 
and women (aged 60–88 years) with low levels of sulfated 
DHEA at baseline, supplementation resulted in signiﬁ  cant 
improvements in BMD at the spine among the women and 
at the hip in both sexes (Jankowski et al 2006); however, 
another double-blind trial in elderly men and women showed 
limited beneﬁ  t after two years of treatment (Nair et al 2006). 
In this trial, the only statistically signiﬁ  cant changes seen 
in the control groups receiving DHEA were an increase in 
total testosterone in men and an increase in BMD at the hip 
in women.
One special population that merits mention is men at 
increased risk of prostate cancer, as there may be concern 
about the safety of testosterone supplementation in these 
patients. Although castration has been associated with regres-
sion or retardation of advanced prostate cancer, it does not 
automatically follow that restoration of normal testosterone 
levels in hypogonadal men increases the risk of carcino-
genesis. In fact, a detailed review on this subject concludes 
that increased risk is associated with low rather than high 
levels of testosterone (Raynaud 2006). In the present study, 
PSA levels increased with GH and/or testosterone, but the 
increases were clinically as well as statistically insigniﬁ  cant, 
as all of the post-treatment values remained well within the 
normal range (0–2.5 ng/mL). Obviously, men with an estab-
lished history of prostate cancer would not be considered 
candidates for treatment.
From the present study, the finding that total and 
free testosterone increased across all treatment groups in 
men, including the control group, indicates that the basic 
regimen of diet and exercise with DHEA and adjunctive 
hormonal correction as needed was also effective, although 
the magnitude of the increase was greater in the Tes and 
Tes+GH groups. Testosterone improved to target ranges 
with all active treatments except Tes+GH; in this group, the 
baseline level of free testosterone was unusually low and the 
post-treatment value, although representing a statistically 
signiﬁ  cant increase, fell just short of the lower limit of the 
target range.
The study left several questions unanswered. Among the 
women, weight decreased more in the control group than 
in the Tes+GH group, which strongly suggests the value of 
lifestyle change and the need to encourage compliance with 
diet and exercise; however, it is not clear why this effect 
was not seen in men.
Another gender issue is the unusually large increase 
in lean mass seen with GH therapy in women but not in 
men. Nor is it clear why women but not men on the control 
regimen showed an unhealthy increase in trunk fat despite 
the reduction in overall fat mass.
DHEA supplementation changes androgen/estrogen 
ratios differently in men and women, which may explain 
our results. There are signiﬁ  cant increases in estrogen levels 
in men, but not much increase in testosterone. For women, 
DHEA increases androgens but does not have much effect Journal of Multidisciplinary Healthcare 2008:1 85
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on estrogens (Arlt et al 1999, 2001; Barnhart et al 1999).
In our study, DHEA did affect testosterone levels in men.
The main limitations of this study are its design as a 
retrospective database survey and the lack of stratiﬁ  cation 
of outcome data by demographic variables other than gender 
and by concurrent treatment modalities. Moreover, although 
diet and exercise counseling was provided to patients, it was 
not feasible to determine the compliance rates. Although the 
current ﬁ  ndings are intriguing, they do not distinguish results 
in younger versus older patients or in patients with different 
levels of endogenous hormones and different measures of 
body composition at baseline. Nevertheless, the results of this 
investigation are important considering the relative paucity of 
long-term data (follow-up 1 year) on outcomes with similar 
treatment strategies. As additional longer-term retrospec-
tive data become available for hormone-deﬁ  cient patients, 
studies that evaluate correlations between administration of 
hormones and speciﬁ  c health outcomes will provide clini-
cians with more precise guidance on which patients to treat 
and which clinical parameters to use as treatment end points. 
By using surrogate measures, such as body composition 
changes, clinicians may be able to more predictably reduce 
cardiovascular disease and cognitive decline.
Randomized controlled prospective clinical trials 
are planned, with larger populations followed for even 
longer periods, which may further clarify the proper role 
of hormonal supplementation as part of a comprehensive 
program to preserve vitality throughout life, improve iden-
tiﬁ  cation of suitable candidates for treatment, and establish 
optimal individualized regimens.
Conclusions
For patients with clinically documented low androgen levels, 
testosterone supplementation, alone or in combination with 
GH (only used in patients who had been diagnosed with adult 
GH deﬁ  ciency), produced clinically signiﬁ  cant changes in (1) 
lean body mass, (2) Beck Depression test, (3) change in total 
body fat, and (4) BMD at the hip in both men and women across 
a wide age range. These results indicate that hormonal supple-
mentation can augment the beneﬁ  ts of lifestyle change.
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GH, growth hormone; PSA, prostate speciﬁ  c antigen.
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